Breaking News

New: DOJ sues to block UnitedHealth takeover of home health giant Amedisys

November 12, 2024
PATRICK T. FALLON/AFP via Getty Images

STAT+ | DOJ sues to block UnitedHealth takeover of home health giant Amedisys

Justice Department files antitrust suit to block UnitedHealth's $3.3 billion acquisition of Amedisys, a home health and hospice care provider

By Bob Herman and Tara Bannow


STAT+ | RNA startup Orna Therapeutics cuts more jobs

Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic to create new, more durable types of RNA-based medicines.

By Allison DeAngelis


STAT+ | Johnson & Johnson sues Biden administration over payment terms for 340B hospitals

J&J recently sought to change 340B payment terms for its Xarelto blood thinner and the Stelara plaque psoriasis treatment.

By Ed Silverman



Mark Palinski at his home in North Carolina. Once asked to leave a Narcotics Anonymous meeting after advocating for the use of buprenorphine to treat opioid use disorder, he now participates in an alternative group, Medication-Assisted Recovery Anonymous.

The recovery community says it offers refuge from opioid addiction. But it's still hostile to lifesaving addiction medications 

Narcotics Anonymous and Salvation Army are often hostile to use of the addiction medications buprenorphine and methadone.

By Lev Facher


STAT+ | FDA commissioner suggests RFK Jr. and Trump might compromise an agency 'at peak performance'

Califf said he was 'disappointed' by the election results and unsure about the future of the agency.

By Lizzy Lawrence


STD epidemic slows as new syphilis and gonorrhea cases fall in U.S.

Cases of the most infectious stages of syphilis fell 10% from the year before — the first big decline in more than two decades.

By Associated Press


Anne Wojcicki is the CEO and co-founder of 23andMe.
Emma McIntyre/Getty Images for MAKERS

STAT+ | The end of 23andMe's drug discovery dream

The genetics startup announced it would lay off 40% of its workforce and halt its efforts to develop new medicines, once a cornerstone of its strategy.

By Matthew Herper


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments